Chien‐Ting Lin

ORCID: 0000-0001-9467-4505
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myeloid Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • RNA Research and Splicing
  • Immune Cell Function and Interaction
  • Retinoids in leukemia and cellular processes
  • Viral-associated cancers and disorders
  • Cancer Genomics and Diagnostics
  • Polyomavirus and related diseases
  • Hematopoietic Stem Cell Transplantation
  • RNA modifications and cancer
  • Digital Imaging for Blood Diseases
  • Nanoparticle-Based Drug Delivery
  • X-ray Diffraction in Crystallography
  • Hepatitis B Virus Studies
  • Folate and B Vitamins Research
  • Single-cell and spatial transcriptomics
  • Immunodeficiency and Autoimmune Disorders
  • Epigenetics and DNA Methylation
  • Fungal Infections and Studies
  • T-cell and B-cell Immunology
  • Vascular Tumors and Angiosarcomas
  • Immunotherapy and Immune Responses

National Taiwan University
2014-2025

National Taiwan University Hospital
2015-2025

Institute of Plant and Microbial Biology, Academia Sinica
2018

National Chung Hsing University
2018

National Tsing Hua University
2016

Children's Nutrition Research Center at Baylor College of Medicine
2016

Genomics Research Center, Academia Sinica
2006-2009

National Yang Ming Chiao Tung University
2005

Multicolor flow cytometry (MFC) analysis is widely used to identify minimal residual disease (MRD) after treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, current manual interpretation suffers from drawbacks of time consuming interpreter idiosyncrasy. Artificial intelligence (AI), with the expertise in assisting repetitive or complex analysis, represents a potential solution these drawbacks.From 2009 2016, 5333 MFC data 1742 AML MDS patients were...

10.1016/j.ebiom.2018.10.042 article EN cc-by-nc-nd EBioMedicine 2018-10-22

// Hsin-An Hou 1 , Chieh-Yu Liu 2 Yuan-Yeh Kuo 3 Wen-Chien Chou 1,4 Cheng-Hong Tsai 1,5 Chien-Chin Lin Liang-In 6 Mei-Hsuan Tseng Ying-Chieh Chiang Ming-Chih 7 Chia-Wen Jih-Luh Tang Ming Yao Chi-Cheng Li Shang-Yi Huang Bor-Sheng Ko Szu-Chun Hsu 4 Chien-Yuan Chen Chien-Ting Shang-Ju Wu Woei Tsay and Hwei-Fang Tien Division of Hematology, Department Internal Medicine, National Taiwan University Hospital, Taipei, Biostatistics Consulting Laboratory, Nursing, Taipei College Graduate Institute...

10.18632/oncotarget.7000 article EN Oncotarget 2016-01-24

Long non-coding RNAs (lncRNAs) represent the majority of cellular transcripts and play pivotal roles in hematopoiesis. However, their clinical relevance acute myeloid leukemia (AML) myelodysplastic syndrome (MDS) remains largely unknown. Here, we investigated functions HOXB-AS3, a lncRNA located at human HOXB cluster, cells, analyzed prognostic significances patients with AML MDS.shRNAs were used to downregulate HOXB-AS3 cell lines effect was evaluated by quantitative polymerase chain...

10.1186/s12885-019-5822-y article EN cc-by BMC Cancer 2019-06-24

We aimed to analyze clinical impacts of the U2AF1 mutation on patients with myelodysplastic syndrome (MDS) and its stability during disease progression. checked status by direct sequencing in 478 de novo MDS correlated characteristics outcomes. also sequentially analyzed 421 samples from 142 determine courses. Thirty-six (7.5%) were found have mutations, which occurred more frequently younger (P = 0.033). was an independent poor-risk factor for overall survival (OS) all 0.030) 0.041). could...

10.1002/ajh.23541 article EN American Journal of Hematology 2013-07-16

Acute myeloid leukaemia (AML) with central nervous system (CNS) involvement in adults is uncommon, and studies of this subject are scant.We conducted a retrospective study to investigate the clinical aspects, cytogenetic abnormalities, molecular gene mutations outcomes adult AML patients CNS involvement. Three hundred ninety-five newly diagnosed were reviewed.Twenty (5.1%) had involvement, including 7 (1.8%) initial disease 4 (1%) who suffered an isolated relapse. The younger, higher...

10.1186/s12885-015-1376-9 article EN cc-by BMC Cancer 2015-05-01

Invasive fungal infections (IFIs) is an important complication for acute myeloid leukemia (AML) patients receiving induction chemotherapy. However, the epidemiological information not clear in Southeastern Asia, area of potential high incidences IFIs. To clarify it, we enrolled 298 non-M3 adult AML chemotherapy without systemic anti-fungal prophylaxis from Jan 2004 to Dec 2009, when applied a prospective diagnostic and treatment algorithm Their demographic parameters, IFI characters, outcome...

10.1371/journal.pone.0128410 article EN cc-by PLoS ONE 2015-06-10

DNMT3A gene mutation has been associated with poor prognosis in acute myeloid leukemia, but its clinical implications myelodysplastic syndrome (MDS) and dynamic changes during disease progression remain controversial. In this study, was identified 7.9% of 469 de novo MDS patients. DNMT3A-mutated patients had higher platelet counts at diagnosis, ring sideroblasts the highest incidence mutations, whereas those multilineage dysplasia lowest incidence. Thirty-one (83.8%) 37 additional molecular...

10.1186/s13148-018-0476-1 article EN cc-by Clinical Epigenetics 2018-04-02

Monoclonal antibodies enhance innate immunity, while bispecific T cell engager redirect adaptive immunity. To stimulate both and mechanisms, we created a bifunctional eCD16A/anti-CD3-BFP adapter protein for combined use with clinically approved monoclonal IgG1 antibodies. The adaptor contains the extracellular domain of human CD16A high-affinity variant, which binds Fc antibodies, an anti-human CD3 single-chain variable fragment that redirects cytotoxicity. Functional characterization was...

10.1080/21645515.2024.2447141 article EN cc-by-nc Human Vaccines & Immunotherapeutics 2025-01-07

Acute myeloid leukemia (AML) with hyperleukocytosis (HL) is intuitively thought as a unique group dismal prognosis. However, comprehensive studies regarding the genetic landscape and clinical outcome in this of patients are limited.A total 693 newly diagnosed de novo non-M3 AML were consecutively enrolled. We compared relevant mutations 20 genes between or without HL exposed their prognostic implications.Hyperleukocytosis, defined initial white blood cell counts above 50 000/μL, occurred...

10.1111/ejh.13073 article EN European Journal Of Haematology 2018-04-06

Abstract Mutations of the GATA binding protein 2 ( GATA2 ) gene in myeloid malignancies usually cluster zinc finger 1 (ZF1) and ZF2 domains. different locations may have distinct impact on clinico-biological features outcomes AML patients, but little is known this aspect. In study, we explored mutations 693 de novo non-M3 patients identified 44 43 (6.2%) including 31 ZF1, 10 ZF2, three outside two Different from mutations, ZF1 were closely associated with French-American-British (FAB) M1...

10.1038/s41408-018-0123-2 article EN cc-by Blood Cancer Journal 2018-08-31

Abstract γδ T cells are a distinct subgroup of that bridge the innate and adaptive immune system can attack cancer in an MHC-unrestricted manner. Trials adoptive cell transfer solid tumors have had limited success. Here, we show DNA methyltransferase inhibitors (DNMTis) upregulate surface molecules on related to activation using quantitative proteomics. DNMTi treatment human lung potentiates tumor lysis by ex vivo-expanded Vδ1-enriched cells. Mechanistically, enhances synapse formation...

10.1038/s41467-021-22433-4 article EN cc-by Nature Communications 2021-04-12

Differences in chronic lymphocytic leukemia between the Asian and Western population are widely known. To further clarify these ethnic differences, we profiled molecular genetics a cohort of 83 newly diagnosed patients from Taiwan. In detail, assessed: (i) usage mutational status clonotypic immunoglobulin heavy-chain variable region (IgHV) genes, (ii) presence VH CDR3 stereotypes, (iii) TP53, NOTCH1, SF3B1, BIRC3, MYD88 mutations. The IgHV gene repertoire was biased distinct that observed...

10.3324/haematol.2016.157552 article EN cc-by-nc Haematologica 2017-03-02

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic malignancies. Although most MDS patients have normal or increased BM cellularity (NH-MDS), some hypocellular (h-MDS). The reports concerning the differences in genetic alterations between h-MDS and NH-MDS limited. In this study, 369 diagnosed according to WHO 2008 criteria were recruited. had lower PB white blood cell blast counts, percentages, than those with NH-MDS. was closely associated lower-risk MDS, defined by...

10.18632/oncotarget.11050 article EN Oncotarget 2016-08-04

Abstract Allogeneic hematopoietic stem cell transplantation is a curative-intent treatment for patients with high-risk hematologic diseases. However, interstitial pneumonitis (IP) and other toxicities remain major concerns after total body irradiation (TBI). We have proposed using linear accelerators rice-bag compensators intensity modulation (IM-TBI), as an alternative to the traditional cobalt-60 teletherapy lung-shielding technique (Co-TBI). Patients who received TBI-based myeloablative...

10.1038/srep36730 article EN cc-by Scientific Reports 2016-11-10

The revised International Prognostic Scoring System (IPSS‐R) was recently developed to better assess the clinical outcome of adult patients with myelodysplastic syndrome (MDS). In this study, we aimed investigate prognostic impact new risk model on 555 MDS in Taiwan. Generally, IPSS‐R could discriminate regarding leukemia evolution and overall survival our cohort it further refined stratification all IPSS categories. However, not find inter‐group difference between very low subgroups both...

10.1002/ajh.23765 article EN American Journal of Hematology 2014-05-21

Chronic lymphocytic leukemia (CLL) is much less prevalent in Asian countries. Whether there are differences survival outcomes between the East and West, however, remain unclear.

10.1371/journal.pone.0062930 article EN cc-by PLoS ONE 2013-04-24
Coming Soon ...